Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,831 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FEAT enhances INSL3 expression in testicular Leydig cells.
Li Y, Kobayashi K, Murayama K, Kawahara K, Shima Y, Suzuki A, Tani K, Takahashi A. Li Y, et al. Among authors: takahashi a. Genes Cells. 2018 Nov;23(11):952-962. doi: 10.1111/gtc.12644. Epub 2018 Oct 2. Genes Cells. 2018. PMID: 30178547 Free article.
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
Murahashi M, Hijikata Y, Yamada K, Tanaka Y, Kishimoto J, Inoue H, Marumoto T, Takahashi A, Okazaki T, Takeda K, Hirakawa M, Fujii H, Okano S, Morita M, Baba E, Mizumoto K, Maehara Y, Tanaka M, Akashi K, Nakanishi Y, Yoshida K, Tsunoda T, Tamura K, Nakamura Y, Tani K. Murahashi M, et al. Among authors: takahashi a. Clin Immunol. 2016 May;166-167:48-58. doi: 10.1016/j.clim.2016.03.015. Epub 2016 Apr 9. Clin Immunol. 2016. PMID: 27072896 Clinical Trial.
Characterization of common marmoset dysgerminoma-like tumor induced by the lentiviral expression of reprogramming factors.
Yamaguchi S, Marumoto T, Nii T, Kawano H, Liao J, Nagai Y, Okada M, Takahashi A, Inoue H, Sasaki E, Fujii H, Okano S, Ebise H, Sato T, Suyama M, Okano H, Miura Y, Tani K. Yamaguchi S, et al. Among authors: takahashi a. Cancer Sci. 2014 Apr;105(4):402-8. doi: 10.1111/cas.12367. Epub 2014 Apr 5. Cancer Sci. 2014. PMID: 24521492 Free PMC article.
TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Narusawa M, Inoue H, Sakamoto C, Matsumura Y, Takahashi A, Inoue T, Watanabe A, Miyamoto S, Miura Y, Hijikata Y, Tanaka Y, Inoue M, Takayama K, Okazaki T, Hasegawa M, Nakanishi Y, Tani K. Narusawa M, et al. Among authors: takahashi a. Cancer Immunol Res. 2014 Jun;2(6):568-80. doi: 10.1158/2326-6066.CIR-13-0143. Epub 2014 Apr 10. Cancer Immunol Res. 2014. PMID: 24830413
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors.
Hijikata Y, Okazaki T, Tanaka Y, Murahashi M, Yamada Y, Yamada K, Takahashi A, Inoue H, Kishimoto J, Nakanishi Y, Oda Y, Nakamura Y, Tani K. Hijikata Y, et al. Among authors: takahashi a. PLoS One. 2018 Jan 2;13(1):e0187878. doi: 10.1371/journal.pone.0187878. eCollection 2018. PLoS One. 2018. PMID: 29293510 Free PMC article. Clinical Trial.
A novel potent tumour promoter aberrantly overexpressed in most human cancers.
Takahashi A, Tokita H, Takahashi K, Takeoka T, Murayama K, Tomotsune D, Ohira M, Iwamatsu A, Ohara K, Yazaki K, Koda T, Nakagawara A, Tani K. Takahashi A, et al. Among authors: takahashi k. Sci Rep. 2011;1:15. doi: 10.1038/srep00015. Epub 2011 Jun 14. Sci Rep. 2011. PMID: 22355534 Free PMC article.
4,831 results